It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease.
‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- Could you give us a brief overview of aspirin exacerbated respiratory disease (AERD), its prevalence and clinical presentation? (0:18)
- What are the treatment options for AERD? (1:51)
- What are the potential advantages of aspirin desensitisation followed by resumption of aspirin therapy and who is most likely to benefit? (2:29)
- What are the mechanisms underlying this beneficial effect? (3:37)
- How long are these beneficial effects maintained? (4:07)
Disclosures: Whitney Stevens discloses participating in advisory boards for GlaxoSmithKline, GenenTech, and Bristol Myers Squibb and participating in an educational lecture symposium for GlaxoSmithKline.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
